No Data
Betta Pharmaceuticals (300558.SZ): No approval or development of projects related to stem cell therapy for tumors.
On November 14th, Betta Pharmaceuticals (300558.SZ) stated on the investor interaction platform that the company has no projects initiated or developed in the field of stem cell therapy for tumors.
Express News | C4 Therapeutics Announced Its Partner Betta Pharmaceuticals Has Dosed The First Patient In The Phase 1 Clinical Trial Of CFT8919, An Orally Bioavailable Allosteric Degrader Of EGFR L858R For Non-small Cell Lung Cancer In Greater China
Betta Pharmaceuticals Co., Ltd. Just Beat EPS By 44%: Here's What Analysts Think Will Happen Next
Betta Pharmaceuticals: Report for the third quarter of 2024
Betta Pharmaceuticals (300558.SZ): The net income in the first three quarters was 0.416 billion yuan, a year-on-year increase of 36.61%.
Gelonghui October 28th | Betta Pharmaceuticals (300558.SZ) announced its third quarter report for 2024. In the first three quarters of 2024, the company achieved revenue of 2.345 billion yuan, a year-on-year increase of 14.73%; net income attributable to shareholders of the listed company was 0.416 billion yuan, a year-on-year increase of 36.61%; net income after deducting non-recurring gains and losses was 0.362 billion yuan, a year-on-year increase of 50.12%; basic earnings per share were 0.99 yuan per share.
Betta Pharmaceuticals Co., Ltd.'s (SZSE:300558) Stock Is Rallying But Financials Look Ambiguous: Will The Momentum Continue?
Betta Pharmaceuticals' (SZSE:300558) Earnings Have Declined Over Three Years, Contributing to Shareholders 62% LossNo Data
No Data
